Citigroup’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.8M | Buy |
1,155,006
+7,358
| +0.6% | +$139K | 0.01% | 1157 |
|
|
2026
Q1 | $25M | Buy |
1,147,648
+1,473
| +0.1% | +$28.5K | 0.01% | 955 |
|
|
2025
Q4 | $24.7M | Buy |
1,146,175
+127,253
| +12% | +$2.68M | 0.01% | 989 |
|
|
2025
Q3 | $19.6M | Buy |
1,018,922
+808,602
| +384% | +$14.4M | 0.01% | 1083 |
|
|
2025
Q2 | $3.6M | Sell |
210,320
-173,507
| -45% | -$7.4M | ﹤0.01% | 2159 |
|
|
2025
Q1 | $24.5M | Buy |
383,827
+309,732
| +418% | +$32.6M | 0.01% | 856 |
|
|
2024
Q4 | $9.01M | Buy |
74,095
+17,335
| +31% | +$2.12M | 0.01% | 1452 |
|
|
2024
Q3 | $7.09M | Buy |
56,760
+24,594
| +76% | +$3.4M | ﹤0.01% | 1554 |
|
|
2024
Q2 | $5.08M | Sell |
32,166
-48,085
| -60% | -$6.18M | ﹤0.01% | 1615 |
|
|
2024
Q1 | $10.4M | Buy |
80,251
+14,865
| +23% | +$1.82M | 0.01% | 1235 |
|
|
2023
Q4 | $6.31M | Buy |
65,386
+19,704
| +43% | +$1.89M | ﹤0.01% | 1452 |
|
|
2023
Q3 | $5.54M | Buy |
45,682
+1,939
| +4% | +$219K | ﹤0.01% | 1376 |
|
|
2023
Q2 | $5.01M | Sell |
43,743
-37,277
| -46% | -$4.81M | ﹤0.01% | 1486 |
|
|
2023
Q1 | $11.2M | Buy |
81,020
+44,517
| +122% | +$5.77M | 0.01% | 1106 |
|
|
2022
Q4 | $4.73M | Sell |
36,503
-29,207
| -44% | -$3.38M | ﹤0.01% | 1502 |
|
|
2022
Q3 | $7.26M | Sell |
65,710
-29,556
| -31% | -$2.98M | 0.01% | 1325 |
|
|
2022
Q2 | $7.14M | Buy |
95,266
+44,525
| +88% | +$3.28M | 0.01% | 1322 |
|
|
2022
Q1 | $3.96M | Sell |
50,741
-31,769
| -39% | -$2.43M | ﹤0.01% | 1812 |
|
|
2021
Q4 | $7.43M | Buy |
82,510
+26,313
| +47% | +$2.25M | ﹤0.01% | 1582 |
|
|
2021
Q3 | $5.2M | Sell |
56,197
-80,125
| -59% | -$6.17M | ﹤0.01% | 1802 |
|
|
2021
Q2 | $10.6M | Buy |
136,322
+41,936
| +44% | +$3.18M | 0.01% | 1371 |
|
|
2021
Q1 | $7.04M | Buy |
94,386
+56,315
| +148% | +$5.2M | ﹤0.01% | 1585 |
|
|
2020
Q4 | $6.49M | Sell |
38,071
-2,078
| -5% | -$308K | ﹤0.01% | 1886 |
|
|
2020
Q3 | $5.64M | Sell |
40,149
-13,836
| -26% | -$2.1M | ﹤0.01% | 1809 |
|
|
2020
Q2 | $8.65M | Buy |
53,985
+1,055
| +2% | +$144K | 0.01% | 1411 |
|
|
2020
Q1 | $5.18M | Sell |
52,930
-24,813
| -32% | -$2.84M | ﹤0.01% | 1642 |
|
|
2019
Q4 | $10M | Sell |
77,743
-1,697
| -2% | -$171K | 0.01% | 1487 |
|
|
2019
Q3 | $5.98M | Sell |
79,440
-145,765
| -65% | -$17.2M | ﹤0.01% | 1781 |
|
|
2019
Q2 | $34.2M | Buy |
225,205
+132,580
| +143% | +$16.1M | 0.03% | 616 |
|
|
2019
Q1 | $11M | Buy |
92,625
+7,973
| +9% | +$1.03M | 0.01% | 1206 |
|
|
2018
Q4 | $9.24M | Buy |
84,652
+30,847
| +57% | +$3.86M | 0.01% | 1314 |
|
|
2018
Q3 | $8.69M | Buy |
53,805
+34,894
| +185% | +$4.77M | 0.01% | 1386 |
|
|
2018
Q2 | $2.5M | Sell |
18,911
-77,302
| -80% | -$7.29M | ﹤0.01% | 2496 |
|
|
2018
Q1 | $7.13M | Sell |
96,213
-47,809
| -33% | -$3.19M | 0.01% | 1483 |
|
|
2017
Q4 | $8.01M | Buy |
144,022
+100,771
| +233% | +$5.34M | 0.01% | 1450 |
|
|
2017
Q3 | $1.96M | Sell |
43,251
-88,443
| -67% | -$3.53M | ﹤0.01% | 2682 |
|
|
2017
Q2 | $4.44M | Buy |
131,694
+62,383
| +90% | +$2.03M | ﹤0.01% | 1796 |
|
|
2017
Q1 | $2.05M | Buy |
69,311
+41,476
| +149% | +$1.28M | ﹤0.01% | 2460 |
|
|
2016
Q4 | $763K | Sell |
27,835
-1,020
| -4% | -$41K | ﹤0.01% | 3963 |
|
|
2016
Q3 | $1.77M | Sell |
28,855
-3,634
| -11% | -$110K | ﹤0.01% | 2634 |
|
|
2016
Q2 | $619K | Sell |
32,489
-50,735
| -61% | -$940K | ﹤0.01% | 3425 |
|
|
2016
Q1 | $1.62M | Buy |
83,224
+41,359
| +99% | +$723K | ﹤0.01% | 2756 |
|
|
2015
Q4 | $1.61M | Buy |
41,865
+12,906
| +45% | +$418K | ﹤0.01% | 2652 |
|
|
2015
Q3 | $929K | Buy |
28,959
+6,658
| +30% | +$226K | ﹤0.01% | 3157 |
|
|
2015
Q2 | $679K | Buy |
22,301
+8,306
| +59% | +$170K | ﹤0.01% | 3434 |
|
|
2015
Q1 | $186K | Sell |
13,995
-6,206
| -31% | -$82.7K | ﹤0.01% | 4593 |
|
|
2014
Q4 | $293K | Buy |
20,201
+15,420
| +323% | +$261K | ﹤0.01% | 4378 |
|
|
2014
Q3 | $101K | Sell |
4,781
-3,269
| -41% | -$73.8K | ﹤0.01% | 4753 |
|
|
2014
Q2 | $240K | Sell |
8,050
-6,749
| -46% | -$213K | ﹤0.01% | 3979 |
|
|
2014
Q1 | $356K | Sell |
14,799
-13,352
| -47% | -$340K | ﹤0.01% | 3803 |
|
|
2013
Q4 | $573K | Buy |
28,151
+17,657
| +168% | +$525K | ﹤0.01% | 3675 |
|
|
2013
Q3 | $495K | Sell |
10,494
-337
| -3% | -$13K | ﹤0.01% | 3451 |
|
|
2013
Q2 | $412K | Buy |
+10,831
| New | +$387K | ﹤0.01% | 3660 |
|
Other funds holding SRPT
EAM
Citigroup's SRPT Position: Q2 2026 in Review
Citigroup increased its Sarepta Therapeutics (SRPT) stake by 0.64% in Q2 2026, buying an estimated $139K and bringing the position to 1,155,006 shares worth $20.8M. The position accounts for 0.01% of the portfolio, ranked #1157.
Citigroup first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $34.2M in Q2 2019. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Citigroup held 1,155,006 shares of Sarepta Therapeutics worth $20.8M as of Q2 2026.
- Citigroup bought 7,358 Sarepta Therapeutics shares in Q2 2026, an estimated $139K.
- Sarepta Therapeutics made up 0.01% of Citigroup's portfolio in Q2 2026, its #1157 holding.
- Citigroup first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Citigroup's Sarepta Therapeutics position peaked at $34.2M in Q2 2019.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.